Tekla Capital Management LLC Arcus Biosciences, Inc. Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
A detailed history of Tekla Capital Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 32,839 shares of RCUS stock, worth $500,137. This represents 0.03% of its overall portfolio holdings.
Number of Shares
32,839
Previous 32,839
-0.0%
Holding current value
$500,137
Previous $598,000
11.37%
% of portfolio
0.03%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
186Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$151 Million0.0% of portfolio
-
State Street Corp Boston, MA4.9MShares$74.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$73 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$43.9 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$29.2 Million0.09% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.1B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...